Argent BioPharma Limited
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more
Argent BioPharma Limited (RGTLF) - Total Assets
Latest total assets as of June 2025: $2.47 Million USD
Based on the latest financial reports, Argent BioPharma Limited (RGTLF) holds total assets worth $2.47 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Argent BioPharma Limited - Total Assets Trend (2020–2025)
This chart illustrates how Argent BioPharma Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Argent BioPharma Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Argent BioPharma Limited's total assets of $2.47 Million consist of 82.3% current assets and 17.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.5% |
| Accounts Receivable | $67.76K | 2.8% |
| Inventory | $132.67K | 5.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Argent BioPharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Argent BioPharma Limited's current assets represent 82.3% of total assets in 2025, an increase from 40.8% in 2020.
- Cash Position: Cash and equivalents constituted 41.5% of total assets in 2025, up from 23.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 5.4% of total assets.
Argent BioPharma Limited Competitors by Total Assets
Key competitors of Argent BioPharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Argent BioPharma Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Argent BioPharma Limited generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Argent BioPharma Limited is currently not profitable relative to its asset base.
Argent BioPharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.19 | 0.23 | 0.19 |
| Quick Ratio | 0.18 | 0.15 | 0.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.80 Million | $ -9.44 Million | $ -10.80 Million |
Argent BioPharma Limited - Advanced Valuation Insights
This section examines the relationship between Argent BioPharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.51 |
| Latest Market Cap to Assets Ratio | 0.80 |
| Asset Growth Rate (YoY) | -77.1% |
| Total Assets | $2.47 Million |
| Market Capitalization | $1.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Argent BioPharma Limited's assets below their book value (0.80 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Argent BioPharma Limited's assets decreased by 77.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Argent BioPharma Limited (2020–2025)
The table below shows the annual total assets of Argent BioPharma Limited from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $2.47 Million | -77.12% |
| 2024-06-30 | $10.79 Million | +8.05% |
| 2023-06-30 | $9.98 Million | -46.20% |
| 2022-06-30 | $18.56 Million | -23.43% |
| 2021-06-30 | $24.24 Million | +205.66% |
| 2020-06-30 | $7.93 Million | -- |